Alliance for Pandemic Preparedness

January 22, 2021

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

Category:

Topic:

Keywords (Tags):

In a phase 2 randomized trial with 577 adult patients with mild to moderate COVID-19, there was no significant difference in the change in SARS-CoV-2 viral load with 3 doses of bamlanivimab, an antispike monoclonal antibody, compared with a placebo. However, treatment with a combination of bamlanivimab and etesevimab, another monoclonal antibody, significantly decreased SARS-CoV-2 viral load at day 11 compared to treatment with placebo. Nine patients reported hypersensitivity reactions, including 6 who received bamlanivimab, 2 who received the combination treatment, and 1 who received placebo.

Gottlieb et al. (Jan 21, 2021). Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19. JAMA. https://doi.org/10.1001/jama.2021.0202